Use of tumor markers in the management of head and neck cancer

International Journal of Biological Markers

Volumn 15, Issue 2, 2000, Pages 179-183

  Rosati, Gerardo ^a,c   Riccardi, F ^b   Tucci, A ^b  

^a SAN CARLO HOSPITAL   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

^c NONE   (Italy)

Author keywords

Head and neck cancer; Tumor markers

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FERRITIN; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CONTROLLED STUDY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; SQUAMOUS CELL CARCINOMA;

EID: 0034094191     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460080001500209     Document Type: Article

References (23)

1. Wolf PL. Tumor associated markers: The importance of identification in clinical medicine. New York: Masson, 1979.
2. Wagener C. Diagnostic sensitivity, diagnostic specificity, and predictive value of the determination of turnor markers. J Clin Chem Clin Biochem 1984; 22: 969-79.
3. Rassekh CH, Johnson JT, Eibling DE. Circulating markers in squamous cell carcinoma of the head and neck: a review. Eur J Cancer 1994; 30B: 23-8.
4. Stieber P, Wollenberg B, Schmitt UM, et al. Clinical relevance of tumour markers in head and neck squamous cell cancer. Tumor Diagn Ther 1996; 4: 116-21.
5. Dreyfuss Al, Clark JR, Andersen JW. Lipid-associated sialic acid, squamous cell carcinoma antigen, carcinoembryonic antigen, and lactic dehydrogenase levels as tumor markers in squamous cell carcinoma of the head and neck. Cancer 1992; 70: 2499-503.
6. Silverman NM, Alexander JC, Chretien PB. CEA levels in head and neck cancer. Cancer 1976; 37: 2204-11.
7. Kuo WR, Tsai SM, Jong SB, Juan KH. Significance of tumour markers in nasopharyngeal carcinoma. J Otolaryngol 1996; 25: 32-6.
8. Nagler RM, Barak M, Peled M, Ben-Aryeh H, Filatov M, Laufer D. Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma. Cancer 1999; 85: 1018-25.
9. Kuo WR, Lee KW, Ho KY, Tsai SM, Chiang FY, Juan KH. Tissue polypeptide antigen, carcinoembryonic antigen, carbohydrate antigen, and CA125 levels as tumor markers in squamous cell carcinoma of the head and neck. Kao Hsiung I Hsueh Ko Hsueh Tsa Chih 1999; 15: 152-8.
10. Maxim PE, Veltri RW. Serum ferritin as a tumor marker in patients with squamous cell carcinoma of the head and neck. Cancer 1986; 57: 305-11.
11. Kato H, Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 1997; 40: 1621-8.
12. Johnson J, Wagner R, Eibling D, et al. Radioimmunoassay for SCC antigen in the diagnosis of squamous cell carcinoma of the head and neck: a preliminary report. In: Kataloff C, deBruijott R, Ebert W, et al, eds. SCC antigen in the management of squamous cell carcinoma. Princeton: Excerpta Medica, 1987; 112-23.
13. Lara PC, Cuyas JM. The role of squamous cell carcinoma antigen in the management of laryngeal and hypopharyngeal cancer. Cancer 1995; 76: 758-64.
14. American Joint Committee for Cancer Staging and Results Reporting. Manual for staging of cancer. Chicago: The American Joint Committee for Cancer Staging, 1978.
15. Liu VY-S, Tobias RJ, Zurawski VR. A more specific, simpler radioimmunoassay for carcinoembryonic antigen, with use of monoclonal antibodies. Clin Chem 1985; 31: 191-5.
16. Mellerick DM, Osborn M, Weber K. On the nature of serological tissue polypeptide antigen (TPA); monoclonal keratin 8, 18 and 19 antibodies react differently with TPA prepared from human cultured carcinoma cells and TPA in human serum. Oncogene 1990; 5: 1007-17.
17. Qvist I, Norden A, Olofsson TJ. Serum ferritin in the elderly. Scand J Clin Lab Invest 1980; 40: 609-13.
18. Castillo I, Gomez F, Guerrero R, et al. Prognostic factors in head and neck cancer patients included in a program of neoadjuvant chemotherapy and clinical radiotherapy. In: Banzet P, Holland JF, Khayat D, eds. Cancer treatment, an update. Paris: Springer-Verlag, 1994; 248-50.
19. Cognetti F, Pinnaro P, Ruggeri EM, et al. Prognostic factors for chemotherapy and survival using combination chemotherapy as initial treatment for advanced head and neck squamous cell cancer. J Clin Oncol 1989; 7: 829-37.
20. Camel JW, Jones AS. Squamous carcinoma of the head and neck: cured fraction and median survival time as functions of age, sex, histologic type, and node status. Br J Cancer 1993; 67: 1071-5.
21. Lorenzi M, Vindigni C, Minacci C, et al. Histopathological and prognostic evaluation of immunohistochemical findings in colorectal cancer, Int J Biol Markers 1997; 12: 68-74.
22. Mevio E, Benazzo M, Galioto P, Spriano P, Pizzala R. Use of serum markers in the diagnosis and management of laryngeal cancer. Clin Otolaryngol 1991; 16: 90-2.
23. Walther EK, Dahlmann N, Gorgulla HT. Tumor markers in the diagnosis and follow-up of head and neck cancer: role of CEA, CA 19-9, SCC, TK and dTTPase. Head Neck 1993; 15: 230-5.